ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
27 Fevereiro 2024 - 9:00AM
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik,
Chief Executive Officer, will present a company overview at the TD
Cowen 44th Annual Health Care Conference on Tuesday, March 5 at
9:50 a.m. ET.
A live webcast of the presentation will be
available via the Events & Presentations page in the Investors
section of ADC Therapeutics’ website, ir.adctherapeutics.com. A
replay of the webcast will be available for approximately 30
days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. In some cases you can identify
forward-looking statements by terminology such as “may”, “will”,
“should”, “would”, “expect”, “intend”, “plan”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “seem”, “seek”,
“future”, “continue”, or “appear” or the negative of these terms or
similar expressions, although not all forward-looking statements
contain these identifying words. Forward-looking statements are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to: the actual
ZYNLONTA® revenue for 4Q 2023, the success of the Company’s updated
corporate strategy including operating efficiencies, capital
deployment and portfolio prioritization; the Company’s ability to
achieve the decrease in total operating expenses for 2023 and 2024,
the expected cash runway into 4Q 2025, the effectiveness of the new
commercial go-to-market strategy, competition from new
technologies, and the Company’s ability to grow ZYNLONTA® revenue
in the United States; Swedish Orphan Biovitrum AB (Sobi®) ability
to successfully commercialize ZYNLONTA® in the European Economic
Area and market acceptance, adequate reimbursement coverage, and
future revenue from the same; approval by the NMPA of the BLA for
ZYNLONTA® in China submitted by Overland ADCT BioPharma and future
revenue from the same, our strategic partners’, including
Mitsubishi Tanabe Pharma Corporation, ability to obtain regulatory
approval for ZYNLONTA® in foreign jurisdictions, and the timing and
amount of future revenue and payments to us from such partnerships;
the impact, if any, from data reported by the University of Miami
for their IIT in FL; the timing and results of the Company’s or its
partners’ clinical trials including LOTIS 5 and 7, ADCT 601 and 602
as well as the Company’s early-stage pipeline research projects,
actions by the FDA or foreign regulatory authorities with respect
to the Company’s products or product candidates; projected revenue
and expenses; the Company’s indebtedness, including Healthcare
Royalty Management and Oaktree and Blue Owl facilities, and the
restrictions imposed on the Company’s activities by such
indebtedness, the ability to repay such indebtedness and the
significant cash required to service such indebtedness; and the
Company’s ability to obtain financial and other resources for its
research, development, clinical, and commercial activities.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the “Risk Factors”
section of the Company's Annual Report on Form 20-F and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this
document. The Company undertakes no obligation to revise or update
these forward-looking statements to reflect events or circumstances
after the date of this press release, except as required by
law.
CONTACTS:
Investors and MediaNicole RileyADC
TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040
ADC Therapeutics (NYSE:ADCT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ADC Therapeutics (NYSE:ADCT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024